Rectal cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 9, 2007, Pages 940-981

  Engstrom, Paul F ^a   Arnoletti, Juan Pablo ^b   Benson III, Al B ^c   Chen, Yi Jen ^d   Choti, Michael A ^e   Cooper, Harry S ^a   Dilawari, Raza A ^f   Early, Dayna S ^g   Fakih, Marwan G ^h   Fuchs, Charles ⁱ   Grem, Jean L ^j   Kiel, Krystyna ^c   Knol, James A ^k   Leong, Lucille A ^d   Ludwig, Kirk A ^l   Martin Jr , Edward W ^m   Rao, Sujata ⁿ   Saltz, Leonard ^o   Shibata, David ^p   Skibber, John M ^q   Venook, Alan P ^r   more..

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^g BARNES JEWISH HOSPITAL   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^j NEBRASKA MEDICAL CENTER   (United States)

^k UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^l DUKE CANCER INSTITUTE   (United States)

^m OHIO STATE UNIVERSITY   (United States)

ⁿ SEATTLE CANCER CARE ALLIANCE   (United States)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^p H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^q UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Adjuvant chemotherapy; Adjuvant radiotherapy; Colorectal surgery; Fluorouracil; Irinotecan; NCCN Clinical Practice Guidelines; Neoplasm recurrence; Neoplasm staging; Oxaliplatin; Rectal neoplasms

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; HUMAN; PRACTICE GUIDELINE; RECTUM CANCER; RECTUM SURGERY; REVIEW;

EID: 35948992985     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0081     Document Type: Review

References (193)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Bonelli L, Martines H, Conio M, et al. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer 1988;41:513-517.
3. Ahsan H, Neugut AI, Garbowski GC, et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998;128:900-905.
4. Greene F, Page D, Fleming I, Fritz A. AJCC Cancer Staging Manual. New York: Springer-Verlag; 2002.
5. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004;54:295-308.
6. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002;236:416-421; discussion 421.
7. Compton CC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000;124:1016-1025.
8. Compton CC. Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med 2006;130:318-324.
9. Lai LL, Fuller CD, Kachnic LA, Thomas CR Jr. Can pelvic radiotherapy be omitted in select patients with rectal cancer? Semin Oncol 2006;33(6 Suppl 11):S70-74.
10. Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol 2002;26:350-357.
11. Wibe A, Rendedal PR, Svensson E, et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002;89:327-334.
12. Stocchi L, Nelson H, Sargent DJ, et al. Impact of surgical and pathologic vatiables in rectal cancer: a United States community and cooperative group report. J Clin Oncol 2001;19:3895-3902.
13. Glynne-Jones R, Mawdsley S, Novell JR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis 2006;8:800-807.
14. Adam IJ, Mohamdee MO, Martin IG, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994;344:707-711.
15. Mawdsley S, Glynne-Jones R, Grainger J, et al. Can histopathologic assessment of circumferential margin aftet preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol Biol Phys 2005;63:745-752.
16. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001;19:157-163.
17. Pocard M, Panis Y, Malassagne B, et al. Assessing the effectiveness of mesorectal excision in rectal cancer: prognostic value of the number of lymph nodes found in resected specimens. Dis Colon Rectum 1998;41:839-845.
18. Wichmann MW, Muller C, Meyer G, et al. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg 2002;137:206-210.
19. Baxter NN, Morris AM, Rothenberger DA, Teppe JE. Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: population based analysis. Int J Radiat Oncol Biol Phys 2005;61:426-431.
20. Turner RR, Nora DT, Trocha SD, Bilchik AJ. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. Arch Pathol Lab Med 2003;127:673-679.
21. Wood TF, Nora DT, Morton DL, et al. One hundred consecutive cases of sentinel node mapping in early colorectal carcinoma. Detection of micrometastasis. J Gastrointest Surg 2002;6:322-330.
22. Noura S, Yamamoto H, Miyake Y, et al. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res 2002;8:759-767.
23. Yasuda K, Adachi Y, Shiraishi N, et al. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol 2001;8:300-304.
24. Braat AE, Oosterhuis JW, Moll FC, et al. Sentinel node detection after preoperative short-course radiotherapy in rectal carcinoma is not reliable. Br J Surg 2005;92:1533-1538.
25. Cooper HS, Deppisch LM, Gourley WK, et al. Endoscopically removed malignant colorectal polyps: clinicopathologic correlations. Gastroenterology 1995;108:1657-1665.
26. Nivatvongs S, Rojanasakul A, Reiman HM, et al. The risk of lymph node metastasis in colorectal polyps with invasive adenocarcinoma. Dis Colon Rectum 1991;34:323-328.
27. Volk EE, Goldblum JR, Petras RE, et al. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology 1995;109:1801-1807.
28. Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004;127:385-394.
29. Seitz U, Bohnacker S, Seewald S, et al. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum 2004;47:1789-1796; discussion 1796-1787.
30. Garcia-Aguilar J, Hernandez de Anda E, Rothenberger DA, et al. Endorectal ulttasound in the management of patients with malignant rectal polyps. Dis Colon Rectum 2005;48:910-916; discussion 916-917.
31. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin 2006;56:143-159; quiz 184-185.
32. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93:583-596.
33. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-646.
34. Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007;25:1014-1020.
35. Weiser MR, Landmann RG, Wong WD, et al. Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum 2005;48:1169-1175.
36. Wiig JN, Larsen SG, Giercksky KE. Operative treatment of locally recurrent rectal cancer. Recent Results Cancer Res 2005;165:136-147.
37. Bartram C, Brown G. Endorectal ultrasound and magnetic resonance imaging in rectal cancer staging. Gastroenterol Clin North Am 2002;31:827-839.
38. Bipat S, Glas AS, Slors FJ, et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging - a meta-analysis. Radiology 2004;232:773-783.
39. Klessen C, Rogalla P, Taupitz M. Local staging of rectal cancer: the current role of MRI. Eur Radiol 2007;17:379-389.
40. Lahaye MJ, Engelen SM, Nelemans PJ, et al. Imaging for predicting the risk factors - the circumferential resection margin and nodal disease - of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR 2005;26:259-268.
41. Beets-Tan RG, Vliegen RF, Beets GL. Magnetic resonance imaging of rectal cancer: what radiation oncologists need to know. Front Radiat Ther Oncol 2004;38:1-12.
42. Guillem JG, Cohen AM. Current issues in colorectal cancer surgery. Semin Oncol 1999;26:505-513.
43. You YN, Baxter NN, Stewart A, Nelson H. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: A nationwide cohort study from the National Cancer Database. Ann Surg 2007;245:726-733.
44. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence ? Br J Surg 1982;69:613-616.
45. Marr R, Birbeck K, Garvican J, et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg 2005;242:74-82.
46. Wagman R, Minsky BD, Cohen AM, et al. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 1998;42:51-57.
47. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus post-operative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
48. Kachnic LA. Should preoperative or postoperative therapy be administered in the management of rectal cancer? Semin Oncol 2006;33(6 Suppl 11):S64-69.
49. Madoff RD. Chemoradiotherapy for rectal cancer - when, why, and how? N Engl J Med 2004;351:1790-1792.
50. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336:980-987.
51. Colorectal Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001;358:1291-1304.
52. Sebag-Montefiore D, Steele R, Quirke P, et al. Routine short course pre-op radiothetapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial [abstract]. J Clin Oncol 2006;24(Suppl 1): Abstract 3511.
53. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with ot without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-4625.
54. Glynne-Jones R, Sebag-Montefiote D. Role of neoadjuvant chemotherapy in rectal cancer: interpretation of the EXPERT study. J Clin Oncol 2006;24:4664-4665; author reply 4665-4666.
55. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiothetapy for rectal cancer: preliminary results - EORTC 22921. J Clin Oncol 2005;23:5620-5627.
56. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-1123.
57. Bujko K, Kepka L, Michalski W, Nowacki MP. Does rectal cancer shrinkage induced by preoperative radio (chemo) therapy increase the likelihood of anterior resection? A systematic review of randomised trials. Radiother Oncol 2006;80:4-12.
58. Wong RK, Tandan V, De Silva S, Figueredo A. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007:CD002102.
59. Peetets KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in itradiated patients - a Dutch colorectal cancer group study. J Clin Oncol 2005;23:6199-6206.
60. Tepper JE, O'Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control-final report of intergroup 0114. J Clin Oncol 2002;20:1744-1750.
61. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004;22:1785-1796.
62. Smalley SR, Benedetti JK, Williamson SK, et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006;24:3542-3547.
63. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-507.
64. Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002;54:403-408.
65. Lin E, Skibber C, Eng C, et al. Phase II study of capecitabine and radiotherapy plus concomitant boost in patients with locally advanced rectal cancer (LARC) [abstract]. J Clin Oncol 2004;22(Suppl 1): Abstract 3775.
66. Glynne-Jones R, Dunst J, Sebag-Montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann Oncol 2006;17:361-371.
67. De Paoli A, Chiara S, Luppi G, et al. A phase II study of capecitabine and pre-operative radiation therapy in resectable, locally advanced rectal cancer [abstract]. J Clin Oncol 2004;22(Suppl 1): Abstract 3540.
68. Krishnan S, Janjan NA, Skibber JM, et al. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2006;66:762-771.
69. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
70. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704.
71. Hong TS, Ritter MA, Tome WA, Harari PM. Intensity-modulated radiation therapy: emerging cancer treatment technology. Br J Cancer 2005;92:1819-1824.
72. Meyer J, Czito B, Yin FF, Willett C. Advanced radiation therapy technologies in the treatment of rectal and anal cancer: intensity-modulated photon therapy and proton therapy. Clin Colorectal Cancer 2007;6:348-356.
73. Valenti V, Balducci M, Tororeto F, et al. Intraoperative radiotherapy: current thinking. Eur J Surg Oncol 2002;28:180-185.
74. Hahnloser D, Haddock MG, Nelson H. Intraoperative radiotherapy in the multimodality approach to colorectal cancer. Surg Oncol Clin N Am 2003;12:993-1013.
75. Willett CG, Czito BG, Tyler DS. Intraoperative radiation therapy. J Clin Oncol 2007;25:971-977.
76. Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004;47:279-286.
77. Tran CL, Udani S, Holt A, et al. Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. Am J Surg 2006;192:873-877.
78. Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000;92:388-396.
79. Benson AB III. New approaches to the adjuvant therapy of colon cancer. Oncologist 2006;11:973-980.
80. Sengupta S, Tjandra JJ. Local excision of rectal cancer: what is the evidence? Dis Colon Rectum 2001;44:1345-1361.
81. Garcia-Aguilar J, Mellgren A, Sirivongs P, et al. Local excision of rectal cancer without adjuvant therapy: a word of caution. Ann Surg 2000;231:345-351.
82. Willett CG, Compton CC, Shellito PC, Efird JT. Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. Cancer 1994;73:2716-2720.
83. Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006;42:2212-2221.
84. Yoo PS, Lopez-Soler RI, Longo WE, Cha CH. Liver resection for metastatic colorectal cancet in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 2006;6:202-207.
85. Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park) 2006;20:1161-1176, 1179; discussion 1179-1180, 1185-1166.
86. Muratore A, Zorzi D, Bouzari H, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007;14:766-770.
87. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243-9249.
88. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-946.
89. Tsai M, Su Y, Ho M, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastases. Ann Surg Oncol 2007;14:786-794.
90. Foster JH. Treatment of metastatic disease of the liver: a skeptic's view. Semin Liver Dis 1984;4:170-179.
91. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:1405-1410.
92. Venook AP. The Kemeny article reviewed. Oncology 2006;20:477-484.
93. Choti MA, Sitzmann J V, Tibuti MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759-766.
94. Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450-457; discussion 457-458.
95. Charnsangavej C, Clary B, Fong Y, et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:1261-1268.
96. Vauthey JN, Zorzi D, Pawlik TM. Making unresectable hepatic colorectal metastases resectable - does it work? Semin Oncol 2005;32(6 Suppl 9):S118-122.
97. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933-939.
98. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311-1319.
99. Abdalla EK, Vauthey JN, Ellis LM, et al. Recuttence and outcomes following hepatic resection, radiofrequency ablation, and combined tesection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-825; discussion 825-817.
100. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemothetapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005;23:2038-2048.
101. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939-3945.
102. Bilchik AJ, Poston G, Curley SA, et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 2005;23:9073-9078.
103. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241:715-722, discussion 722-714.
104. Elias D, Liberale G, Vernerey D, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005;12:900-909.
105. Fong Y, Salo J. Surgical therapy of hepatic colorectal metastasis. Semin Oncol 1999;26:514-523.
106. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-657; discussion 657-648.
107. Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol 2005;16:425-429.
108. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-180.
109. Bevacizumab [package insert]. South San Francisco, CA: Genentech Inc.; 2006.
110. Lee WS, Yun SH, Chun HK, et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007;22:699-704.
111. Headrick JR, Miller DL, Nagorney DM, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975-979; discussion 979-980.
112. Kemeny N, Ron I. Hepatic arterial chemothetapy in metastatic colorectal patients. Semin Oncol 1999;26:524-535.
113. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-2048.
114. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 2002;20:1499-1505.
115. Lowy AM, Rich TA, Skibber JM, et al. Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally advanced pelvic recurrence of colorectal adenocarcinoma. Ann Surg 1996;223:177-185.
116. Hoffman JP, Riley L, Carp NZ, Litwin S. Isolated locally recurrent rectal cancer: a review of incidence, presentation, and management. Semin Oncol 1993;20:506-519.
117. Pelosi E1 Deandreis D. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol 2007;33:1-6.
118. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006;11:1010-1017.
119. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005;23:4553-4560.
120. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006;24:3347-3353.
121. Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist 2006;11:981-987.
122. Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12:38-50.
123. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
124. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807-814.
125. Pettelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluotouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:1559-1565.
126. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-4106.
127. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-1197.
128. Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA in stage III colon cancer patients (pts). (PETACC3) [abstract]. J Clin Oncol 2005;23(Suppl 1):3s. Abstract 8.
129. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12: 14-20.
130. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-815.
131. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338-1342.
132. Peeters M, Van Cutsem E, Sienna S, et al. A phase 3 multicenter randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients with metastatic colorectal cancer [abstract]. American Association for Cancer Research 2006 Annual Meeting: Abstract CP-1.
133. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
134. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25(2Suppl 5):4-12.
135. O'Dwyer PJ. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist 2006;11:992-998.
136. Lentz F, Tran A, Rey E, et al. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics 2005;5:21-33.
137. Rothenbetg ML, Blanke CD. Topoisomerase I inhibitors in the treatment of colorectal cancer. Semin Oncol 1999;26:632-639.
138. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
139. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
140. Cheeseman SL, Joel SP, Chester JD, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 2002;87:393-399.
141. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
142. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-4875.
143. Cassidy J, Clarke S, Diaz-Rubio E, et al. Fitst efficacy and safety results from XELOX-1/N016966, a randomized 2x2 factorial phase III trial of XELOX vs. FOLFOX6 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann Oncol 2006;17(Suppl 9): LBA3.
144. Arkenau H, Schmoll H, Kubicka S, et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): results of the safety and efficacy analysis [abstract]. J Clin Oncol 2005;23(Suppl 1): Abstract 3507.
145. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancet. J Clin Oncol 2004;22:2084-2091.
146. Andre T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:1343-1347.
147. Jager E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996;14:2274-2279.
148. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-1887.
149. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705.
150. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502-3508.
151. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712.
152. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
153. Hochster H, Hart LL, Ramanathan R, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE study [abstract]. J Clin Oncol 2006;24(Suppl 1): Abstract 3510.
154. Hochstet H, Welles L, Hart L, et al. Safety and efficacy of bevicizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 studies [abstract]. J Clin Oncol 2005;23 (Suppl 1): Abstract 3515.
155. Fuchs C, Marshall J, Mitchell E, et al. Updated results of BICC-C study comparing first-line irinotecan /fluoropyrimidine combinations +/- celecoxib in mCRC: Clinical data cut-off September 1, 2006. Presented at 2007 ASCO Gastrointestinal Cancers Symposium, January 19-21, 2007; Orlando, Florida. Abstract 276.
156. Sobero A, Ackland S, Carrion R, et al. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer [abstract]. J Clin Oncol 2006;24(Suppl 1):157s. Abstract 3544.
157. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
158. Capecitabine [package insert]. Nutley, NJ: Roche Laboratories Inc.; 2005.
159. Haller D, Cassidy J, Clarke S, et al. Toletability of fluoropyrimidines appears to differ by region [abstract]. J Clin Oncol 2006;24(Suppl 1):148s. Abstract 3514.
160. Schmoll HJ, Arnold D. Update on capecitabine in colorectal cancer. Oncologist 2006;11:1003-1009.
161. Itinotecan hydrochloride injection [package insert]. New York, NY: Pfizer; 2006.
162. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-1388.
163. LabCorp Capsule. UGT1A1 Irinotecan Toxicity. Managing medication dosing and predicting response to treatment of cancer with itinotecan (Camptosar, CPT-11). Available at http://www.labcotp.com. Accessed December I, 2006.
164. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyl-transferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006;24:4534-4538.
165. Oxaliplatin [package insert]. Bedford, OH: Ben Venue Laboratories; 2004.
166. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a CERCOR study. J Clin Oncol 2006;24:394-400.
167. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
168. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
169. Cunningham D, Pyrhonen S, James RD, et al. Randomised ttial of itinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
170. Pitot HC, Rowland KM, Satgent DJ, et al. N9841: a randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) inpatients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU [abstract]. J Clin Oncol 2005;23(Suppl 1):247s. Abstract 3506.
171. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
172. Cetuximab [package insert]. Branchburg, NJ: Imclone Systems, Inc.; 2004.
173. Panitumumab [package insert]. Thousand Oaks, CA: Amgen; 2006.
174. Hecht J, Mitchell E, BarandaJ, et al. Panitumumab antitumot activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (< 1%) levels of epidermal growth receptor (EGFR) [abstract]. J Clin Oncol 2006;24(Suppl 1):157s. Abstract 3547.
175. Hoff PM, Pazdut R, Lassere Y, et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004;22:2078-2083.
176. Pietra N, Sarli L, Costi R, et al. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998;41:1127-1133.
177. Secco GB, Fardelli R, Gianquinto D, et al. Efficacy and cost of risk-3 adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002;28:418-423.
178. Rodriguez-Moranta F, Salo J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 2006;24:386-393.
179. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004;22:3395-3407.
180. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002;324:813.
181. Jeffery M, Hickey B, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007:CD002200.
182. Desch CE, Benson AB III, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23:8512-8519.
183. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664-8670.
184. Guyot F, Faivre J, Manfredi S, et al. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol 2005;16:756-761.
185. Pfister DG, Benson AB III, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004;350:2375-2382.
186. Li Destri G, Di Cataldo A, Puleo S. Colorectal cancer follow-up: useful or useless? Surg Oncol 2006;15:1-12.
187. Locker GY, Hamilton S, Hatris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327.
188. Macdonald JS. Carcinoembryonic antigen screening: pros and cons. Semin Oncol 1999;26:556-560.
189. Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin 2006;56:160-167; quiz 185-166.
190. Grossmann I, de Bock GH, Meershoek-Klein Kranenbarg WM, et al. Carcinoembryonic antigen (CEA) measurement during follow-up for rectal carcinoma is useful even if normal levels exist before surgery. A retrospective study of CEA values in the TME trial. Eur J Surg Oncol 2007;33:183-187.
191. Green RJ, Metlay JP, Propert K, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002;136:261-269.
192. Martin EW Jr, Minton JP, Carey LC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg1985;202:310-317.
193. Moffat FL Jr, Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscintigtaphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol 1996;14:2295-2305.